“…Unlike in the case of 99m Tc-pyrophosphate, a large amount of data support the clinical use of 111 In-antimyosin for the detection of acute or chronic diffuse myocardial damage in several clinical settings other than MI, such as allograft rejection in cardiac transplant recipients [25,26,27,28,29], doxorubicin-induced cardiotoxicity [20,30,31,32], acute myocarditis [19,33,34,35], various cardiomyopathies [21,36,37,38,39] or diseases secondary to myocardial involvement [40,41,42,43,44]. The performance of 111 In-antimyosin scanning in pathological conditions characterised by ongoing and diffuse myocardial necrosis is of potential clinical value considering that the serum concentration of the biological markers of myocardial injury may not be sufficient for the diagnosis or staging of the damage in these heart diseases.…”